J. Pawlotsky, Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in??Interferon-Free Regimens, Gastroenterology, vol.151, issue.1, pp.70-86, 2016.
DOI : 10.1053/j.gastro.2016.04.003

S. Zeuzem, M. Mizokami, S. Pianko, A. Mangia, K. Han et al., NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome European-Association-for-the-Study-of-the-Liver. EASL Recommendations on Treatment of Hepatitis C 2016, J Hepatol J Hepatol, vol.366, pp.153-194, 2017.

E. Lawitz, F. Poordad, J. Guttierez, J. Wells, C. Landaverde et al., weeks of Elbasvir/Grazoprevir with Sofosbuvir and Ribavirin Successfully Treated GT1-infected Subjects who Failed Short-Duration All-Oral Therapy, Part B Hepatology, vol.62, p.121386, 2015.

E. Lawitz, F. Poordad, J. Gutierrez, T. Kakuda, G. Picchio et al., LP07 : Simeprevir (SMV) plus daclatasvir (DCV) and sofosbuvir (SOF) in treatment-na??ve and -experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: Interim results from the phase II impact study, Journal of Hepatology, vol.62, p.7, 2015.
DOI : 10.1016/S0168-8278(15)30161-6

M. Reig, Z. Marino, C. Perello, M. Inarrairaegui, A. Ribeiro et al., Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy, Journal of Hepatology, vol.65, issue.4
DOI : 10.1016/j.jhep.2016.04.008

F. Conti, F. Buonfiglioli, A. Scuteri, C. Crespi, L. Bolondi et al., Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with directacting antivirals Clinical outcomes in HCV-infected patients treated with direct acting antivirals-18 month post-treatment follow-up in the French ANRS CO22 HEPATHER Cohort Study. ANRS/AFEF HEPATHER Study Group, S2) : LB505. 10, pp.727-733, 2016.

R. Waziry, B. Hajarizadeh, J. Grebely, J. Amin, M. Law et al., No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression, S12. 11. Bourliere M, 2017.
DOI : 10.1016/S0168-8278(17)30286-6

E. Lawitz, F. Poordad, J. Wells, R. Hyland, Y. Yang et al., Sofosbuvirvelpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV, Hepatology, vol.13, 2017.

E. Lawitz, N. Reau, F. Hinestrosa, M. Rabinovitz, E. Schiff et al., Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With??Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial, Gastroenterology, vol.151, issue.5, pp.893-901, 2016.
DOI : 10.1053/j.gastro.2016.07.039